US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Arin Tactical Tail Risk ETF

91.40

+0.16030.18%

Volume:178.00

Turnover:16.27K

Market Cap:89.49M

PE:- -

High:91.40

Open:91.40

Low:91.40

Close:91.24

52wk High:91.40

52wk Low:45.10

Shares:979.15K

Float Shares:959.15K

Volume Ratio:0.04

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Alnylam: ATTR Franchise Momentum and Strategic Investment Support Durable Growth and Buy Rating

Alnylam: Profitability Milestone and ATTR Momentum Underpin Durable Double-Digit Growth and Buy Rating

Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety Event - Has The Bull Case Changed?

Simply Wall St.

Bayer’s New Phase 4 ATTR-CM Study Tests Switching From Tafamidis to Acoramidis

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

1 Stock Up by 63% This Year That Could Double, According to Wall Street

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ATTR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATTR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","market":"US","secType":"STK","nameCN":"Arin Tactical Tail Risk ETF","latestPrice":91.3999,"timestamp":1771621200000,"preClose":91.2396,"halted":0,"volume":178,"delay":0,"changeRate":0.001756912568665432,"floatShares":959146,"shares":979146,"eps":0,"marketStatus":"Market Closed","change":0.1603,"latestTime":"02-20 16:00:00 EST","open":91.4,"high":91.4,"low":91.3999,"amount":16266.728,"amplitude":0.000001,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":91.2396,"sharesOutstanding":979146,"nav":91.3,"aum":89396029.8,"bidAskSpread":0,"volumeRatio":0.04269404366090544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","floatShares":959146,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.04269404366090544,"shares":979146,"dividePrice":0,"high":91.4,"amplitude":0.000001,"preClose":91.2396,"low":91.3999,"week52Low":45.1,"pbRate":"--","week52High":91.4,"institutionHeld":0,"latestPrice":91.3999,"eps":0,"divideRate":0,"volume":178,"delay":0,"ttmEps":0,"open":91.4,"prevYearClose":90.4492,"prevWeekClose":91.1336,"prevMonthClose":91.0958,"prevQuarterClose":90.4492,"fiveDayClose":91.2651,"twentyDayClose":90.9344,"sixtyDayClose":90.0911},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATTR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATTR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATTR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATTR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611874971","title":"Alnylam: ATTR Franchise Momentum and Strategic Investment Support Durable Growth and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2611874971","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611874971?lang=en_us&edition=fundamental","pubTime":"2026-02-13 02:25","pubTimestamp":1770920724,"startTime":"0","endTime":"0","summary":"Analyst Joseph Stringer of Needham maintained a Buy rating on Alnylam Pharma, reducing the price target to $510.00. Joseph Stringer has given his B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alnylam-attr-franchise-momentum-and-strategic-investment-support-durable-growth-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alnylam-attr-franchise-momentum-and-strategic-investment-support-durable-growth-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATTR"],"gpt_icon":0},{"id":"2611978004","title":"Alnylam: Profitability Milestone and ATTR Momentum Underpin Durable Double-Digit Growth and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2611978004","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611978004?lang=en_us&edition=fundamental","pubTime":"2026-02-12 23:55","pubTimestamp":1770911745,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has maintained their bullish stance on ALNY stock, giving a Buy rating on January 30. Myles Minter has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alnylam-profitability-milestone-and-attr-momentum-underpin-durable-double-digit-growth-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alnylam-profitability-milestone-and-attr-momentum-underpin-durable-double-digit-growth-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATTR"],"gpt_icon":0},{"id":"2607104040","title":"Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2607104040","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607104040?lang=en_us&edition=fundamental","pubTime":"2026-01-31 00:31","pubTimestamp":1769790694,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc ($NTLA) announced an update on their ongoing clinical study. Study Overview – Intellia Therapeutics is running a Phase 1 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/intellias-ntla-2001-hits-key-milestone-in-attr-gene-editing-trial-raising-the-stakes-in-amyloidosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/intellias-ntla-2001-hits-key-milestone-in-attr-gene-editing-trial-raising-the-stakes-in-amyloidosis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","NTLA","BK4556","BK4535","BK4585","LU1861559042.SGD","BK4139","ATTR","BK4588"],"gpt_icon":0},{"id":"2606782835","title":"Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN","url":"https://stock-news.laohu8.com/highlight/detail?id=2606782835","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606782835?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518800,"startTime":"0","endTime":"0","summary":"Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan.  27, 2026  (GLOBE NEWSWIRE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226448/0/en/Intellia-Therapeutics-Announces-FDA-Lift-of-Clinical-Hold-on-MAGNITUDE-2-Phase-3-Clinical-Trial-in-ATTRv-PN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4139","BK4183","BK4535","IE0009354923.USD","LU1861559042.SGD","BK4556","BK4585","ATTR","LU1861558580.USD","ODD","NTLA","BK4588"],"gpt_icon":0},{"id":"2603628923","title":"Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety Event - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603628923","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603628923?lang=en_us&edition=fundamental","pubTime":"2026-01-15 04:26","pubTimestamp":1768422396,"startTime":"0","endTime":"0","summary":"In early January 2026, Intellia Therapeutics reported a fatal safety event and Grade 4 liver abnormalities in its Phase 3 MAGNITUDE ATTR-CM trial, prompting the FDA to place both MAGNITUDE and MAGNITUDE-2 studies on clinical hold while the company works with regulators on a path forward for nexiguran ziclumeran (nex-z).\nThis setback for Intellia’s lead in vivo CRISPR program sharply elevates its regulatory and development risk profile, particularly given the company’s reliance on a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-up-207-after-fda-halts-magnitu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-up-207-after-fda-halts-magnitu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4556","NTLA","BK4585","LU1861559042.SGD","CM","BK4207","ATTR","BK4535","BK4139","LU1861558580.USD"],"gpt_icon":0},{"id":"2602237009","title":"Bayer’s New Phase 4 ATTR-CM Study Tests Switching From Tafamidis to Acoramidis","url":"https://stock-news.laohu8.com/highlight/detail?id=2602237009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602237009?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:33","pubTimestamp":1767976395,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Bayer Explores Switch to New ATTR-CM Therapy in Phase 4 Study The study, off...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayers-new-phase-4-attr-cm-study-tests-switching-from-tafamidis-to-acoramidis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayers-new-phase-4-attr-cm-study-tests-switching-from-tafamidis-to-acoramidis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4116","LU1093756168.USD","ATTR","BK4207","LU1093756325.SGD","SWCH","CM","BK4513"],"gpt_icon":0},{"id":"2581486586","title":"Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2581486586","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581486586?lang=en_us&edition=fundamental","pubTime":"2025-11-08 23:41","pubTimestamp":1762616460,"startTime":"0","endTime":"0","summary":"- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/08/3184066/0/en/Acoramidis-Significantly-Reduces-All-cause-Mortality-in-the-Overall-ATTR-CM-Variant-and-V142I-V122I-Populations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNV92.GBP","BK4081","BK4162","LU0289961442.SGD","LU1939255532.USD","BBIO","BK4129","ACM","IE00B42XCP33.USD","LU0289739343.SGD","LU2244417387.USD","IE00BGHQDM52.EUR","LU2308191902.HKD","IE00BVYPNP33.GBP","IE00BVYPNW00.USD","AFL","EMA","BK4505","BK4585","LU0511384066.AUD","IE00B3PB1722.GBP","IE00BDGV0183.EUR","IE00BGHQF631.EUR","LU2298064838.USD","LU0057025933.USD","BK4516","BK4139","CM","LU0472753341.HKD","LU0069063385.USD","LU0689626769.HKD","ATTR","BK4588","LU0187121727.USD","BK4207","LU2238339852.HKD","LU0124676726.USD","IE00BVYPNQ40.USD"],"gpt_icon":0},{"id":"2580029008","title":"BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580029008","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580029008?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:30","pubTimestamp":1762173000,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., Nov.  03, 2025  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179150/0/en/BridgeBio-to-Present-Data-from-the-Overall-ATTR-CM-Variant-and-V142I-V122I-Populations-from-ATTRibute-CM-at-the-AHA-Scientific-Sessions-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CM","BK4207","ATTR"],"gpt_icon":0},{"id":"2578648062","title":"Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)","url":"https://stock-news.laohu8.com/highlight/detail?id=2578648062","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578648062?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:30","pubTimestamp":1761564600,"startTime":"0","endTime":"0","summary":"Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct.  27, 2025  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174462/0/en/Intellia-Therapeutics-Provides-Update-on-MAGNITUDE-Clinical-Trials-of-Nexiguran-Ziclumeran-nex-z.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4556","BK4588","CRSP","IE0009354923.USD","BK4535","NTLA","BK4183","ATTR","BK4139","ODD","LU1861559042.SGD","LU1861558580.USD","BK4611"],"gpt_icon":0},{"id":"2573924963","title":"1 Stock Up by 63% This Year That Could Double, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2573924963","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573924963?lang=en_us&edition=fundamental","pubTime":"2025-10-07 21:45","pubTimestamp":1759844700,"startTime":"0","endTime":"0","summary":"Some math suggests that even Wall Street is lowballing the stock's potential.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835831%2Fscientist-altering-dna-genome-project.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835831%2Fscientist-altering-dna-genome-project.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/07/1-stock-up-by-63-this-year-that-could-double/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/07/1-stock-up-by-63-this-year-that-could-double/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00B19Z6F94.USD","LU1169589451.USD","ATTR","IE0034390439.USD","IE00B64QTZ34.USD","HAE","BK4198","LU0106261612.USD","LU1169590202.USD","LU0205193047.USD","IE00BLDYK493.USD","LU0205194284.USD","LU0012050646.USD"],"gpt_icon":0},{"id":"2570557828","title":"Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM","url":"https://stock-news.laohu8.com/highlight/detail?id=2570557828","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570557828?lang=en_us&edition=fundamental","pubTime":"2025-09-28 23:15","pubTimestamp":1759072500,"startTime":"0","endTime":"0","summary":"- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the  cumulative risk of CVM or recurrent CVH through Month 30 ver","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/28/3157362/0/en/Acoramidis-Begins-to-Reduce-Cumulative-Cardiovascular-Outcomes-Within-the-First-Month-of-Treatment-in-Patients-with-ATTR-CM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2308191902.HKD","BK4505","BK4585","BK4139","BK4129","BK4188","ATTR","BK4516","ACM","BK4082","LU0689626769.HKD","CM","BK4588","LU0124676726.USD","CSII","ASM","BK4207","BBIO","CVM"],"gpt_icon":0},{"id":"2570301564","title":"Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2570301564","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570301564?lang=en_us&edition=fundamental","pubTime":"2025-09-25 21:52","pubTimestamp":1758808320,"startTime":"0","endTime":"0","summary":"One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinica","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/25/3156402/0/en/Intellia-Therapeutics-Announces-Positive-Longer-Term-Phase-1-Data-for-Nexiguran-Ziclumeran-nex-z-in-Patients-with-Hereditary-Transthyretin-ATTR-Amyloidosis-with-Polyneuropathy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861559042.SGD","BK4585","NTLA","BK4556","CRSP","BK4139","BK4611","BK4535","LU1861558580.USD","ATTR"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}